$87.21
-0.30-0.34%
Last update: Nov 10, 7:24 PM
BioNTech SE
BNTXNASDAQ
BioNTech fell 19.5% from $108.65 to $87.51, behind the S&P 500's +9.8%. Its worst day was Mar 10 (−17.9%), and its low came Mar 10 at $83.89.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BioNTech closed at its highest level of the year, 9.8% above where the year started.
+1.1% · S&P 500 +0.4%
EPS of $-0.38 beat the $-0.47 estimate on $1.1B revenue (est. $889.5M); FY revenue guidance of $2.3B–$2.7B against the $3.1B consensus.
Story events cover the past 12 months · Times ET
−17.9%, the year's worst day, on 13M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-2.28 beat the $-2.52 estimate on $138.0M revenue (est. $214.6M); FY revenue guidance of $2.3B–$2.7B against the $2.6B consensus.
−3.9% · S&P 500 +0.8%
EPS of $-2.58 missed the $-2.34 estimate on $122.8M revenue (est. $182.0M); FY revenue guidance of $1.9B–$2.2B against the $2.5B consensus.
−1.0% · S&P 500 +1.8%
BioNTech shares rose 22.0%, while the S&P 500 rose 0.2%.
+22.0%, the year's best day · S&P 500 +0.2%
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
−8.4% · S&P 500 −0.2%
EPS of $2.03 beat the $0.97 estimate on $1.5B revenue (est. $1.2B); FY revenue guidance of $2.0B–$2.2B against the $2.0B consensus.
−0.7% · S&P 500 +0.3%
Where it ended: a close of $87.51 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 9, 2027 (EPS est. $-1.41, revenue est. $603.0M).
Nothing in the past 12 months.
All BNTX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BNTX and SPY from Benzinga historical bars. Not investment advice.
